Aktis Oncology (AKTS) director Sherman discloses two stock option awards

Rhea-AI Filing Summary

Aktis Oncology director Michael A. Sherman filed a report of his beneficial ownership of stock options in Aktis Oncology, Inc. On January 8, 2026, he held a stock option for 74,913 shares of common stock at an exercise price of $9.14, expiring on October 8, 2035. Twenty‑five percent of these shares vest on August 1, 2026, with the remainder vesting in equal monthly installments, subject to his continued service. He also held a second stock option for 18,933 shares at an exercise price of $18, expiring on January 7, 2036, which vests in full on January 8, 2027 if he remains in service.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Sherman Michael A.

(Last) (First) (Middle)

C/O AKTIS ONCOLOGY, INC.

17 DRYDOCK AVENUE, SUITE 17-401

(Street)

BOSTON MA 02210

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
01/08/2026

3. Issuer Name and Ticker or Trading Symbol
Aktis Oncology, Inc. [ AKTS ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	(1)	10/08/2035	Common Stock	74,913	$9.14	D
Stock Option (Right to Buy)	(2)	01/07/2036	Common Stock	18,933	$18	D

Explanation of Responses:

1. 25% of the original number of shares subject to the option shall vest on August 1, 2026, and 1/48th of the original number of shares subject to the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each vesting date, inclusive.

2. The number of shares subject to the option shall vest in full on January 8, 2027, subject to the Reporting Person's continuous service through such vesting date.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Michael A. Sherman	01/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Aktis Oncology (AKTS) disclose in this Form 3 filing?

The filing reports director Michael A. Sherman’s beneficial ownership of two stock option awards for Aktis Oncology common stock, including their exercise prices, share amounts, terms, and vesting schedules as of January 8, 2026.

How many Aktis Oncology stock options does Michael A. Sherman report holding?

He reports holding two stock options: one covering 74,913 shares of common stock and another covering 18,933 shares of common stock.

What are the exercise prices of Michael A. Sherman’s Aktis Oncology options?

The larger option has an exercise price of $9.14 per share, and the second option has an exercise price of $18 per share.

When do Michael A. Sherman’s Aktis Oncology options expire?

The 74,913‑share option expires on October 8, 2035. The 18,933‑share option expires on January 7, 2036.

How do the vesting terms work for the 74,913-share Aktis Oncology option?

For the 74,913‑share option, 25% of the original shares vest on August 1, 2026, and 1/48th of the original shares then vest in monthly installments, subject to continuous service through each vesting date.

When does the 18,933-share Aktis Oncology option vest?

The 18,933‑share option is scheduled to vest in full on January 8, 2027, provided Michael A. Sherman continues to serve through that date.